中国癌症杂志 ›› 2022, Vol. 32 ›› Issue (4): 335-342.doi: 10.19401/j.cnki.1007-3639.2022.04.006
收稿日期:
2021-02-25
修回日期:
2021-07-25
出版日期:
2022-04-30
发布日期:
2022-05-07
通信作者:
张国强
E-mail:xbq14lc@163.com;zhangguoqiang@hrbmu.edu.cn
作者简介:
许炳琦(ORCID: 0000-0002-0304-6747),硕士研究生在读 E-mail: xbq14lc@163.com
XU Bingqi()(
), ZHANG Guoqiang(
)(
)
Received:
2021-02-25
Revised:
2021-07-25
Published:
2022-04-30
Online:
2022-05-07
Contact:
ZHANG Guoqiang
E-mail:xbq14lc@163.com;zhangguoqiang@hrbmu.edu.cn
文章分享
摘要:
随着乳腺癌新辅助治疗的发展,病理学完全缓解率明显提高。对于已经达到病理学完全缓解的患者,使用局域放疗替代手术治疗在理论上可行,因此术前准确判断病理学完全缓解至关重要。新辅助化疗后二次活检因其对病理学完全缓解预测准确率较高而被认为是有希望替代手术诊断病理学完全缓解的方法。最近发表的几项国外的前瞻性临床试验结果表明,新辅助化疗后二次活检具有相对较高的假阴性率,对新辅助化疗反应极好的患者豁免手术仍需要进一步研究。本文首先阐述二次活检的临床应用及其意义,并将国外已发表的临床研究分为小型可行性研究和大型前瞻性研究,对其主要结果及特点进行分析。
中图分类号:
许炳琦, 张国强. 乳腺癌新辅助治疗二次活检诊断病理学应答研究进展及临床意义[J]. 中国癌症杂志, 2022, 32(4): 335-342.
XU Bingqi, ZHANG Guoqiang. Advances in the diagnosis of pathological response by a second biopsy in breast cancer neoadjuvant therapy and their clinical significance[J]. China Oncology, 2022, 32(4): 335-342.
表1
新辅助化疗效果评估方法的优缺点"
Approach | Clinical examination | Mammography | Ultrasound | MRI | Second biopsy |
---|---|---|---|---|---|
Advantages | Simple and convenient | High sensitivity | Easy to operate and free of radiation; High accuracy; Assessable for axillary response; | High resolution for soft tissue; Non-invasive and free of radiation; Highest accuracy in traditional radiology | Higher accuracy than MRI; Lower false-negative rate |
Disadvantages | Effect by subjective judgement; Lower accuracy than other approaches | Effect by breast density, benign calcification and artifacts etc.; Exposure to radiation; Axillary status cannot be assessed; Difficult to distinguish the residual disease and post-chemotherapy fibrosis | Highly effect by the operator; High false positive rate | Expensive; Risk of contrast agent sensitization | Invasive; Required marker clips; Accuracy depends on the size of needle and number of specimens; Guided by imaging |
表2
活检预测pCR小型前瞻性研究"
Study | Eligibility criteria | Number of patients | Type of biopsy | Type of guidance | Results |
---|---|---|---|---|---|
Heil, et al.[ | Early breast cancer; cCR after NACT | 164 | 111 by CC and 46 by VAB | 143 by ultrasound; 20 by mammograph; 1 by unknow | NPV=71.3% FNR=49.3% |
Heil, et al.[ | Operable breast cancer; cCR/cPR after NACT; target lesion visible on ultrasound | 50 | VAB | Ultrasound | Entire cohort: NPV=76.7%; FNR=49.3%; Pathologic representative specimens: NPV=94.4%; FNR=4.8% |
MD Anderson Cancer Center[ | TNBC and HER2+ breast caner; Lesion size < 5 cm on imaging after NACT | 40 | VAB and FNA; median sampling number of 12 | 63% by stereotactic techniques; 37% by ultrasound | Accuracy=98%; FNR=5%; NPV=95% |
NOSTRA PRELIM[ | Invasive breast cancer regardless of subtypes; Received NACT | 20 | CNB; median sampling number of 4 | Ultrasound | Cases of false negative of 4/18 |
Lee, et al.[ | Near pCR after NACT (Size of lesion≤0.5 cm or L-to-B SER ≤1.6 on MRI) | 40 | CNB or VAB | MRI assisted ultrasound | NPV=87.1%; FNR=30.8%; Accuracy=90% |
表3
活检预测pCR大型前瞻性研究"
Study group | Eligibility criteria | Type of biopsy | Number of patients | Unique features | Results |
---|---|---|---|---|---|
MICRA[ | Invasive breast cancer; No metastasis; rPR/rCR by CE-MRI after NACT | Ultrasound-guided 14G biopsies targeted around pre-NACT-placed marker (4 central and 4 peripheral) | 167 (still recruiting) | Included all subtypes; Assessing response by CE-MRI | FNR=37% |
RESPONDER[ | Invasive breast cancer; cCR/PR; Visible targeted lesion on ultrasound/mammography | Ultrasound/mammography guided VAB | 398 | pCR identified by VAB | FNR=17.8% (95% CI: 12.8%-23.7%) |
NRG-BR005[ | Unifocal or multifocal; cCR after NACT; rCR/nearCR by triple- modality radiology; Patients must have a biopsy marker placed within the tumor bed with imaging confirmation of marker placement prior to NST | 6, 8, 11G VAB, stereotactic-guided | 98 (still recruiting) | Multicenter, triple-modality radiology was required | FNR=50% NPV=77.5% (95% CI: 66.8%-86.1%) |
Multicenter pooled analysis[ | Invasive breast cancer; Any subtypes; At least achieved rCR; Marker/residual tumor/microcalcification can be clearly identified within the primary lesion location | VAB/CNB; Ultrasound or stereotactic | 166 | Multicenter pooled data analysis | FNR=18.7% NPV=84.3% |
[1] | CASTRELLON A B,, PIDHORECKY I,, VALERO V, et al. The role of carboplatin in the neoadjuvant chemotherapy treatment of triple negative breast cancer[J]. Oncol Rev, 2017, 11(1): 324. |
[2] |
GIANNI L,, PIENKOWSKI T,, IM Y H, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial[J]. Lancet Oncol, 2012, 13(1): 25-32.
doi: 10.1016/S1470-2045(11)70336-9 |
[3] |
GOLSHAN M,, CIRRINCIONE C T,, SIKOV W M, et al. Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage Ⅱ-Ⅲ HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance)[J]. Breast Cancer Res Treat, 2016, 160(2): 297-304.
doi: 10.1007/s10549-016-4006-6 |
[4] | GOLSHAN M,, CIRRINCIONE C T,, SIKOV W M, et al. Impact of neoadjuvant chemotherapy in stage Ⅱ-Ⅲ triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance)[J]. Ann Surg, 2015, 262(3): 434-439; discussion 438-439. |
[5] |
RING A,, WEBB A,, ASHLEY S, et al. Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer?[J]. J Clin Oncol, 2003, 21(24): 4540-4545.
doi: 10.1200/JCO.2003.05.208 |
[6] |
VAN LA PARRA R F D,, KUERER H M. Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials[J]. Breast Cancer Res, 2016, 18(1): 28.
doi: 10.1186/s13058-016-0684-6 |
[7] |
PEINTINGER F,, KUERER H M,, ANDERSON K, et al. Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy[J]. Ann Surg Oncol, 2006, 13(11): 1443-1449.
doi: 10.1245/s10434-006-9086-9 |
[8] |
KEUNE J D,, JEFFE D B,, SCHOOTMAN M, et al. Accuracy of ultrasonography and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancer[J]. Am J Surg, 2010, 199(4): 477-484.
doi: 10.1016/j.amjsurg.2009.03.012 |
[9] |
SHAH S K,, SHAH S K,, GREATREX K V. Current role of magnetic resonance imaging in breast imaging: a primer for the primary care physician[J]. J Am Board Fam Pract, 2005, 18(6): 478-490.
doi: 10.3122/jabfm.18.6.478 |
[10] |
CROSHAW R,, SHAPIRO-WRIGHT H,, SVENSSON E, et al. Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining post neoadjuvant pathologic tumor response in operable breast cancer patients[J]. Ann Surg Oncol, 2011, 18(11): 3160-3163.
doi: 10.1245/s10434-011-1919-5 |
[11] |
KUERER H M,, VRANCKEN PEETERS M T F D,, REA D W, et al. Nonoperative management for invasive breast cancer after neoadjuvant systemic therapy: conceptual basis and fundamental international feasibility clinical trials[J]. Ann Surg Oncol, 2017, 24(10): 2855-2862.
doi: 10.1245/s10434-017-5926-z |
[12] |
HEIL J,, KÜMMEL S,, SCHAEFGEN B, et al. Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques[J]. Br J Cancer, 2015, 113(11): 1565-1570.
doi: 10.1038/bjc.2015.381 |
[13] |
MAURI D,, PAVLIDIS N,, IOANNIDIS J P A. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis[J]. J Natl Cancer Inst, 2005, 97(3): 188-194.
doi: 10.1093/jnci/dji021 |
[14] |
RASTOGI P,, ANDERSON S J,, BEAR H D, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27[J]. J Clin Oncol, 2008, 26(5): 778-785.
doi: 10.1200/JCO.2007.15.0235 |
[15] |
CORTAZAR P,, ZHANG L J,, UNTCH M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis[J]. Lancet, 2014, 384(9938): 164-172.
doi: 10.1016/S0140-6736(13)62422-8 |
[16] |
ZHANG Y,, SHEN J P,, WU S Y, et al. The use of a second core needle biopsy to predict response to neoadjuvant chemotherapy in breast cancer patients, especially in the HER2-positive population[J]. Surgery, 2020, 168(6): 1115-1121.
doi: 10.1016/j.surg.2020.06.045 |
[17] |
MASUDA N,, LEE S J,, OHTANI S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy[J]. N Engl J Med, 2017, 376(22): 2147-2159.
doi: 10.1056/NEJMoa1612645 |
[18] |
VON MINCKWITZ G,, HUANG C S,, MANO M S, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer[J]. N Engl J Med, 2019, 380(7): 617-628.
doi: 10.1056/NEJMoa1814017 |
[19] |
VON MINCKWITZ G,, KÜMMEL S,, VOGEL P, et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase Ⅲ randomized GeparTrio trial[J]. J Natl Cancer Inst, 2008, 100(8): 542-551.
doi: 10.1093/jnci/djn085 |
[20] | 邵志敏,, 江泽飞,, 李俊杰, 等. 中国乳腺癌新辅助治疗专家共识(2019年版)[J]. 中国癌症杂志, 2019, 29(5): 390-400. |
SHAO Z M,, JIANG Z F,, LI J J, et al. Expert consensus on neoadjuvant therapy for breast cancer in China (2019 edition)[J]. China Oncol, 2019, 29(5): 390-400. | |
[21] | 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2021年版)[J]. 中国癌症杂志, 2021, 31(10): 954-1040. |
The Society of Breast Cancer China Anti-Cancer Association. Guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2021 edition)[J]. China Oncol, 2021, 31(10): 954-1040. | |
[22] | 中国临床肿瘤学会指南工作委员会组织. 中国临床肿瘤学会(CSCO)乳腺癌诊疗指南-2021[M]. 北京: 人民卫生出版社, 2021. |
[23] |
SPRING L M,, FELL G,, ARFE A, et al. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis[J]. Clin Cancer Res, 2020, 26(12): 2838-2848.
doi: 10.1158/1078-0432.CCR-19-3492 |
[24] |
XIE Y F,, WU S Y,, ZHANG Y, et al. Optimal duration of neoadjuvant taxane and carboplatin combined with anti-HER2 targeted therapy for HER2-positive breast cancer[J]. Front Oncol, 2021, 11: 686591.
doi: 10.3389/fonc.2021.686591 |
[25] |
HEIL J,, SCHAEFGEN B,, SINN P, et al. Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy?[J]. Eur J Cancer, 2016, 69: 142-150.
doi: 10.1016/j.ejca.2016.09.034 |
[26] |
KUERER H M,, RAUCH G M,, KRISHNAMURTHY S, et al. A clinical feasibility trial for identification of exceptional responders in whom breast cancer surgery can be eliminated following neoadjuvant systemic therapy[J]. Ann Surg, 2018, 267(5): 946-951.
doi: 10.1097/SLA.0000000000002313 |
[27] | FRANCIS A,, HERRING K,, MOLYNEUX R, et al. Abstract P5-16-14: NOSTRA PRELIM: a non randomised pilot study designed to assess the ability of image guided core biopsies to detect residual disease in patients with early breast cancer who have received neoadjuvant chemotherapy to inform the design of a planned trial[C]//. Poster Session Abstracts. American Association for Cancer Research, 2017. |
[28] |
LEE H B,, HAN W,, KIM S Y, et al. Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial[J]. Breast Cancer Res Treat, 2020, 182(1): 97-105.
doi: 10.1007/s10549-020-05678-3 |
[29] | LOEVEZIJN A V,, VAN DER NOORDAA M E M,, VAN WERKHOVEN E, et al. Minimally invasive complete response assessment of the breast after neoadjuvant systemic therapy (MICRA trial): interim analysis of a multicenter observational cohort study[J]. Eur J Cancer, 2020, 138: S9-S10. |
[30] | HEIL J,, PFOB A,, SINN H P P, et al. Abstract GS5-03: Diagnosing residual disease and pathologic complete response after neoadjuvant chemotherapy in breast cancer patients by image-guided vacuum-assisted breast biopsy: results of a prospective multicenter trial[C]// . General session abstracts. American Association for Cancer Research, 2020. |
[31] | MARK BASIK R S C,, JENNIFER F DE LOS SANTOS H R U,, THOMAS B JULIAN E P M, et al. Abstract GS5-05: primary analysis of NRG-BR005, a phase Ⅱ trial assessing accuracy of tumor bed biopsies in predicting pathologic complete response (pCR) in patients with clinical/radiological complete response after neoadjuvant chemotherapy (NCT) to explore the feasibility of breast-conserving treatment without surgery[C]. 2020, 80(Suppl 4): 5. |
[32] |
TASOULIS M K,, LEE H B,, YANG W, et al. Accuracy of post-neoadjuvant chemotherapy image-guided breast biopsy to predict residual cancer[J]. JAMA Surg, 2020, 155(12): e204103.
doi: 10.1001/jamasurg.2020.4103 |
[33] |
VAN DER NOORDAA M E M,, VAN DUIJNHOVEN F H,, LOO C E, et al. Identifying pathologic complete response of the breast after neoadjuvant systemic therapy with ultrasound guided biopsy to eventually omit surgery: study design and feasibility of the MICRA trial (minimally invasive complete response assessment)[J]. Breast, 2018, 40: 76-81.
doi: 10.1016/j.breast.2018.04.015 |
[34] |
HEIL J,, SINN P,, RICHTER H, et al. RESPONDER-diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast cancer-a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial[J]. BMC Cancer, 2018, 18(1): 851.
doi: 10.1186/s12885-018-4760-4 |
[35] |
LI Y,, ZHOU Y D,, MAO F, et al. The diagnostic performance of minimally invasive biopsy in predicting breast pathological complete response after neoadjuvant systemic therapy in breast cancer: a meta-analysis[J]. Front Oncol, 2020, 10: 933.
doi: 10.3389/fonc.2020.00933 |
[36] |
PFOB A,, SIDEY-GIBBONS C,, LEE H B, et al. Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by an intelligent vacuum-assisted biopsy[J]. Eur J Cancer, 2021, 143: 134-146.
doi: 10.1016/j.ejca.2020.11.006 |
[1] | 伍雯, 张若昕, 翁俊勇, 马延磊, 蔡国响, 李心翔, 杨永志. 探索阳性淋巴结比率在ypⅢ期结直肠癌患者中的预后价值及预测模型的建立[J]. 中国癌症杂志, 2024, 34(9): 873-880. |
[2] | 徐睿, 王泽浩, 吴炅. 肿瘤相关中性粒细胞在乳腺癌发生、发展中的作用研究进展[J]. 中国癌症杂志, 2024, 34(9): 881-889. |
[3] | 曹晓珊, 杨蓓蓓, 丛斌斌, 刘红. 三阴性乳腺癌脑转移治疗的研究进展[J]. 中国癌症杂志, 2024, 34(8): 777-784. |
[4] | 张剑. 关于女性乳腺癌患者绝经状态判断两个关键问题的临床思考[J]. 中国癌症杂志, 2024, 34(7): 619-627. |
[5] | 姜丹, 宋国庆, 王晓丹. 乳腺癌中线粒体功能障碍与CPT1A/ERK信号转导通路共同调节乳腺癌恶性行为的机制研究[J]. 中国癌症杂志, 2024, 34(7): 650-658. |
[6] | 董涧桥, 李坤艳, 李菁, 王斌, 王艳红, 贾红燕. SIRT3通过去乙酰化YME1L1诱导乳腺癌内分泌治疗耐药的作用机制研究[J]. 中国癌症杂志, 2024, 34(6): 537-547. |
[7] | 郝弦, 黄建军, 杨文秀, 刘晋廷, 张军红, 罗钰蓓, 李青, 王大红, 高玉炜, 谭福云, 薄莉, 郑羽, 王荣, 冯江龙, 李静, 赵春华, 豆晓伟. 乳腺癌原代细胞系为药物筛选和基础研究提供癌症新模型[J]. 中国癌症杂志, 2024, 34(6): 561-570. |
[8] | 薛驰, 高鹏, 朱志, 王振宁. 免疫治疗在胃癌的围手术期及转化治疗中的应用和挑战[J]. 中国癌症杂志, 2024, 34(3): 259-267. |
[9] | 中国抗癌协会乳腺癌专业委员会. 中国早期乳腺癌卵巢功能抑制临床应用专家共识(2024年版)[J]. 中国癌症杂志, 2024, 34(3): 316-333. |
[10] | 张琪, 修秉虬, 吴炅. 2023年中国乳腺癌重要临床研究成果及最新进展[J]. 中国癌症杂志, 2024, 34(2): 135-142. |
[11] | 张思源, 江泽飞. 2023年改变晚期乳腺癌临床实践的重要研究成果及进展[J]. 中国癌症杂志, 2024, 34(2): 143-150. |
[12] | 王昭卜, 黎星, 于鑫淼, 金锋. 2023年改变早期乳腺癌临床实践的重要研究成果及进展[J]. 中国癌症杂志, 2024, 34(2): 151-160. |
[13] | 罗扬, 孙涛, 邵志敏, 崔久嵬, 潘跃银, 张清媛, 程颖, 李惠平, 杨燕, 叶长生, 于国华, 王京芬, 刘运江, 刘新兰, 周宇红, 柏玉举, 谷元廷, 王晓稼, 徐兵河, 宋礼华. AK-HER2与参照药治疗HER2阳性转移性乳腺癌患者的疗效、体内代谢特征、安全性和免疫原性比较:一项多中心、随机、双盲Ⅲ期等效性临床试验[J]. 中国癌症杂志, 2024, 34(2): 161-175. |
[14] | 陈远香, 余涛, 杨诗雨, 曾涛, 魏兰, 张彦. KDM4A通过下调BMP9促进乳腺癌细胞MDA-MB-231的迁移和侵袭[J]. 中国癌症杂志, 2024, 34(2): 176-184. |
[15] | 胡晓钰, 蔡毓文, 叶富贵, 邵志敏, 胡伟刚, 余科达. BRCA1/2胚系突变对三阴性乳腺癌患者放疗后第二原发肿瘤的影响[J]. 中国癌症杂志, 2024, 34(2): 185-190. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||
地址:上海市徐汇区东安路270号复旦大学附属肿瘤医院10号楼415室
邮编:200032 电话:021-64188274 E-mail:zgazzz@china-oncology.com
访问总数:; 今日访问总数:; 当前在线人数:
本系统由北京玛格泰克科技发展有限公司设计开发 技术支持:support@magtech.com.cn